ArTara Therapeutics Inc (TARA)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
Jesse Shefferman
Employees:
30
1 LITTLE WEST 12TH STREET NEW YORK NY 10014
646-844-0337

Protara Therapeutics, Inc. engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the. treatment of lymphatic malformations. It also develops intravenous choline chloride, an. investigational phospholipid substrate replacement therapy.

Data derived from most recent annual or quarterly report
Market Cap 32.224 Million Shares Outstanding11.307 Million Avg 30-day Volume 33.129 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.8
Price to Revenue0.0 Debt to Equity0.0 EBITDA-42.778 Million
Price to Book Value0.0 Operating Margin0.0 Enterprise Value0
Current Ratio0 EPS Growth-0.189 Quick Ratio0
1 Yr BETA 1.0411 52-week High/Low 4.6 / 2.38 Profit Margin0.0
Operating Cash Flow Growth-19.027 Altman Z-Score0.0 Free Cash Flow to Firm 1.559 Million
Earnings Report2023-08-08
View SEC Filings from TARA instead.

View recent insider trading info

ArTara Therapeutics Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding TARA (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding TARA

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 5: filed on 2023-02-10 by SHEFFERMAN JESSE
  • 4: filed on 2023-01-30 by FABBIO PATRICK
  • 4: filed on 2023-01-20 by SHEFFERMAN JESSE
  • 4: filed on 2023-01-20 by FRY HANNAH
  • 4: filed on 2023-01-20 by ZUMMO JACQUELINE
  • 4: filed on 2023-01-20 by BANDARI JATHIN
  • 4: filed on 2023-01-11 by ZUMMO JACQUELINE
  • 4: filed on 2023-01-11 by SHEFFERMAN JESSE
  • 4: filed on 2023-01-11 by BANDARI JATHIN
  • 4: filed on 2023-01-04 by ZUMMO JACQUELINE

    • Events (8k)

  • 8-K: filed on 2023-05-04:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-05-02:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-04-28:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-03-10:
    Item 7.01: Regulation FD Disclosure
  • 8-K: filed on 2023-03-08:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-01-30:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-01-05:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-03:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-09:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-07-18:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    FABBIO PATRICK CHIEF FINANCIAL OFFICER

    • Officer
    		 300,000 2023-01-30 2

    ZUMMO JACQUELINE CHF SCIENTIFIC OPERATIONS OFF

    • Officer
    		 210,773 2023-01-19 3

    SHEFFERMAN JESSE CEO AND PRESIDENT

    • Officer
    • Director
    		 1,225,782 2023-01-19 5

    BANDARI JATHIN CHIEF MEDICAL OFFICER

    • Officer
    		 163,542 2023-01-19 3

    FRY HANNAH VP, CONTROLLER

    • Officer
    		 68,539 2023-01-19 4

    OPALEYE MANAGEMENT INC.

    • 10% Owner
    		 2,692,594 2022-12-30 2

    DAVIS BLAINE CHIEF FINANCIAL OFFICER

    • Officer
    		 20,662 2022-07-15 1

    BESHAR LUKE M

    • Director
    		 198,000 2022-06-30 2

    SARGEN GREGORY

    • Director
    		 10,000 2022-06-08 1

    GARCEAU ROGER

    • Director
    		 10,000 2022-06-08 1

    LEVY RICHARD S

    • Director
    		 10,000 2022-06-08 1

    SMITH CYNTHIA

    • Director
    		 10,000 2022-06-08 1

    FLANNELLY BARRY P

    • Director
    		 10,000 2022-06-08 1

    HUANG JANE

    • Director
    		 10,000 2022-06-08 1

    SOLOMON MICHAEL EDWARD

    • Director
    		 10,000 2022-06-08 1

    OLIVO MARTIN SEBASTIAN CHIEF MEDICAL OFFICER

    • Officer
    		 14,344 2021-06-10 0

    MARSHALL RANDALL

    • FORMER 10% OWNER
    		 No longer subject to file 2020-09-14 0

    BRAUNSTEIN SCOTT

    • Director
    		 0 2020-06-09 0

    OPALEYE, L.P.

    • 10% Owner
    		 2,208,472 2020-01-09 0

    CASOY JULIO CHIEF MEDICAL OFFICER

    • Officer
    		 45,500 2020-01-09 0

    ABINGWORTH LLP

    • FORMER 10% OWNER
    		 No longer subject to file 2019-11-12 0

    HAINES TIMOTHY

    • FORMER DIRECTOR AND 10% OWNER
    		 No longer subject to file 2019-11-12 0

    FREUND JOHN GORDON

    • Director
    		 2,175,882 2019-11-08 0

    BURKE STEVEN KEITH SVP AND CHIEF MEDICAL OFFICER

    • Officer
    		 147,248 2019-03-15 0

    NOYES TIMOTHY P PRESIDENT AND CEO

    • Officer
    • Director
    		 0 2019-01-31 0

    GOTTLIEB DANIEL PHILIP VP CORPORATE DEVELOPMENT

    • Officer
    		 0 2019-01-18 0

    ELDRIDGE, GEORGE ARTHUR SR VP, CFO, TREASR, ASST SECY

    • Officer
    		 0 2019-01-18 0

    TONER E. SCOTT SENIOR VP OF COMMERCIAL

    • Officer
    		 0 2019-01-18 0

    KOWALSKY MATTHEW PAUL VP, LEGAL AND SECRETARY

    • Officer
    		 0 2019-01-18 0

    HARTMAN BRADLEY J VP, PEOPLE

    • Officer
    		 0 2019-01-18 0

    FLYNN JAMES E

    DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)

    • Director
    • *DIRECTOR BY DEPUTIZATION*DIRECTOR BY DEPUTIZATION
    		 0 2018-06-08 0

    LEFF JONATHAN S

    • Director
    		 0 2018-06-08 0

    BOHLIN GAREN G

    • Director
    		 0 2018-06-08 0

    CANUTE SCOTT A

    • Director
    		 0 2018-06-08 0

    HASTINGS PAUL J

    • Director
    		 0 2018-06-08 0

    KINGSLEY STUART A

    • Director
    		 0 2018-06-08 0

    BIRNER HUBERT

    • Director
    • 10% Owner
    		 0 2018-06-08 0

    FLYNN JAMES E

    DEERFIELD MANAGEMENT CO

    DEERFIELD MGMT L.P.

    DEERFIELD PARTNERS, L.P.

    DEERFIELD INTERNATIONAL MASTER FUND, L.P.

    • Director
    • 10% Owner
    • *DIRECTOR BY DEPUTIZATION*DIRECTOR BY DEPUTIZATION*DIRECTOR BY DEPUTIZATION*DIRECTOR BY DEPUTIZATION*DIRECTOR BY DEPUTIZATION
    		 1,224,899 2017-11-30 0

    FLYNN JAMES E

    DEERFIELD PRIVATE DESIGN FUND III, L.P.

    DEERFIELD SPECIAL SITUATIONS FUND, L.P.

    DEERFIELD INTERNATIONAL MASTER FUND, L.P.

    DEERFIELD PARTNERS, L.P.

    DEERFIELD PRIVATE DESIGN FUND IV, L.P.

    DEERFIELD MGMT L.P.

    DEERFIELD MGMT III, L.P.

    DEERFIELD MGMT IV, L.P.

    DEERFIELD MANAGEMENT CO

    • Director
    • *DIRECTOR BY DEPUTIZATION*DIRECTOR BY DEPUTIZATION*DIRECTOR BY DEPUTIZATION*DIRECTOR BY DEPUTIZATION*DIRECTOR BY DEPUTIZATION*DIRECTOR BY DEPUTIZATION*DIRECTOR BY DEPUTIZATION*DIRECTOR BY DEPUTIZATION*DIRECTOR BY DEPUTIZATION*DIRECTOR BY DEPUTIZATION
    		 1,224,899 2017-08-02 0

    TVM LIFE SCIENCE VENTURES VI GMBH & CO KG

    TVM LIFE SCIENCE VENTURES VI LP

    BIRNER HUBERT

    FISCHER STEFAN

    SCHUHSLER HELMUT

    • Director
    • 10% Owner
    		 1,000 2017-06-22 0

    O'LEARY BRENDAN

    • Director
    		 0 2016-06-09 0

    PHELPS GREGORY D

    • Director
    		 0 2015-06-02 0

    KOBYZEV DMITRY

    • Director
    • 10% Owner
    		 0 2015-06-02 0

    FLYNN JAMES E

    DEERFIELD MGMT L.P.

    DEERFIELD MANAGEMENT CO

    DEERFIELD SPECIAL SITUATIONS FUND, L.P.

    DEERFIELD SPECIAL SITUATIONS INTERNATIONAL MASTER FUND, L.P.

    DEERFIELD MGMT III, L.P.

    DEERFIELD PRIVATE DESIGN FUND III, L.P.

    • 10% Owner
    • POSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUP
    		 No longer subject to file 2014-10-27 0

    TVM LIFE SCIENCE VENTURES VI GMBH & CO KG

    FISCHER STEFAN

    GOLL ALEXANDRA

    SCHUHSLER HELMUT

    TVM LIFE SCIENCE VENTURES VI LP

    • 10% Owner
    		 3,846,186 2014-10-27 0

    SKYLINE VENTURE PARTNERS QUALIFIED PURCHASER FUND IV L P

    SKYLINE VENTURE MANAGEMENT IV, LLC

    FREUND JOHN GORDON

    KANEKO YASUNORI

    • 10% Owner
    		 1,432,930 2014-10-27 0

    PRISM VENTURE PARTNERS V L P

    PRISM VENTURE PARTNERS V-A LP

    • 10% Owner
    		 No longer subject to file 2014-10-27 0

    PHARMSTANDARD INTERNATIONAL S.A.

    PUBLIC JOINT STOCK CO PHARMSTANDARD

    • 10% Owner
    		 1,165,344 2014-10-27 0

    PRISM VENTURE PARTNERS V L P

    • Director
    • 10% Owner
    		 0 2014-10-21 0

    PRISM VENTURE PARTNERS V L P

    O'LEARY BRENDAN

    PRISM VENTURE PARTNERS V-A LP

    • Director
    • 10% Owner
    		 0 2014-10-21 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    PROTARA THERAPEUTIC INC TARA 2023-06-06 22:15:03 UTC 3.2725 1.7975 150000
    PROTARA THERAPEUTIC INC TARA 2023-06-06 21:45:05 UTC 3.2725 1.7975 150000
    PROTARA THERAPEUTIC INC TARA 2023-06-06 21:15:04 UTC 3.2725 1.7975 150000
    PROTARA THERAPEUTIC INC TARA 2023-06-06 20:45:04 UTC 3.2725 1.7975 150000
    PROTARA THERAPEUTIC INC TARA 2023-06-06 20:15:04 UTC 3.2725 1.7975 150000
    PROTARA THERAPEUTIC INC TARA 2023-06-06 19:45:04 UTC 3.2725 1.7975 150000
    PROTARA THERAPEUTIC INC TARA 2023-06-06 19:15:03 UTC 3.2725 1.7975 150000
    PROTARA THERAPEUTIC INC TARA 2023-06-06 18:45:04 UTC 3.2725 1.7975 150000
    PROTARA THERAPEUTIC INC TARA 2023-06-06 18:15:04 UTC 3.2725 1.7975 150000
    PROTARA THERAPEUTIC INC TARA 2023-06-06 17:45:04 UTC 3.2725 1.7975 150000
    PROTARA THERAPEUTIC INC TARA 2023-06-06 17:15:04 UTC 3.2725 1.7975 200000
    PROTARA THERAPEUTIC INC TARA 2023-06-06 16:45:04 UTC 3.2625 1.7975 200000
    PROTARA THERAPEUTIC INC TARA 2023-06-06 16:15:03 UTC 3.2625 1.7975 150000
    PROTARA THERAPEUTIC INC TARA 2023-06-06 15:45:04 UTC 3.2625 1.7975 150000
    PROTARA THERAPEUTIC INC TARA 2023-06-06 15:15:04 UTC 3.2625 1.7975 150000
    PROTARA THERAPEUTIC INC TARA 2023-06-06 14:45:04 UTC 3.2639 1.7961 150000
    PROTARA THERAPEUTIC INC TARA 2023-06-06 14:15:03 UTC 3.2639 1.7961 200000
    PROTARA THERAPEUTIC INC TARA 2023-06-06 13:45:03 UTC 3.2639 1.7961 200000
    PROTARA THERAPEUTIC INC TARA 2023-06-06 13:15:03 UTC 3.2639 1.7961 200000
    PROTARA THERAPEUTIC INC TARA 2023-06-06 12:45:05 UTC 3.2639 1.7961 200000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments